Research Article
A Novel Glucose Metabolism-Related Gene Signature for Overall Survival Prediction in Patients with Glioblastoma
Table 3
Associations between the signature risk score and clinical features.
| | Clinical feature | Risk score | 2 | | | High-risk (%) | Low-risk (%) |
| | Gender | | | 0.011 | 0.917 | | Female | 29(49.15%) | 30(50.85%) | | | | Male | 54(50.00%) | 54(50.00%) | | | | Age | | | 3.974 | 0.046 | | <65 | 47(43.93%) | 60(56.07%) | | | | ≥65 | 36(60.00%) | 24(40.00%) | | | | KPS | Fisher’s exact test | 0.572 | | <60 | 3(42.86%) | 4(57.14%) | | | | ≥60 | 55(47.01%) | 62(52.99%) | | | | Transcriptome subtype | Fisher’s exact test | <0.0001 | | Classical | 20(38.46%) | 32(61.54%) | | | | Mesenchymal | 54(73.97%) | 19(26.03%) | | | | Neural | 4(57.14%) | 3(42.86%) | | | | Proneural | 1(5.26%) | 18(94.74%) | | | | IDH1 status | | | 7.669 | 0.006 | | Wild | 78(52.35%) | 71(47.65%) | | | | Mutant | 1(9.09%) | 10(90.91%) | | | | MGMT promoter status | | 1.271 | 0.260 | | Unmethylated | 37(50.00%) | 37(50.00%) | | | | Methylated | 22(40.00%) | 33(60.00%) | | |
|
|
